Idera Pharma chief upbeat despite setback in Merck KGaA pact; InSite Vision raising $22.2M in financing;

@FierceBiotech: Superbug antibiotics: New drugs advance amid R&D investment shortfall. Special Report | Follow @FierceBiotech

> Xconomy caught up with Idera Pharmaceuticals ($IDRA) after the developer of drugs that target Toll-like receptors suffered a setback last week in its collaboration with German drug maker Merck KGaA. Idera, as the story notes, is still working with the other Merck ($MRK) and has money in the bank to continue its research. Article

> InSite Vision ($INSV), a developer of eye treatments, says that expects to receive gross proceeds of $22.2 million through a private placement of the firm's common stock and warrants. Release

> Array BioPharma ($ARRY) said has licensed a cancer drug called ARRY-543, which is entering Phase II trials, to Singapore-based ASLAN Pharmaceuticals. Item

> PharmaGap, an Ontario-based developer of peptide drugs, said it has competed the first close of a private financing for a total of $500,000. Announcement

> Montreal-based Thallion Pharmaceuticals ($TLN) said it has temporarily stopped the screening and enrollment of a high-dose cohort in a Phase II study of an antibody treatment in patients with STEC infections, as a precautionary measure after observing an "out-of-specification" finding in stability testing. Release

Pharma News

@FiercePharma: Novartis mulls IPO on China's planned int'l board. News | Follow @FiercePharma

> Studies: Gilead HIV drugs prevent transmission. Report

> Justice hits J&J with misdemeanor in Natrecor probe. Article

> Note to Pfizer: Bayer shopping for vet buys. Item

> Penn prof files complaint over ghostwritten Paxil study. News

> As rumors swirl, Shire eyes Vyvanse for binge eating. Article

> Hospitals want action on 'unprecedented' drug shortages. Report

Drug Delivery News

> Alnylam applies for trial of RNAi delivery tech for high cholesterol. Item

> MIT's Langer discusses targeted drug delivery. Report

> EnGeneIC, scientists search for antibodies to grab hold of tumors. Item

> Multitasking gel, polymer chain could deliver many drugs at once. Article

> Instant nano-delivery vehicle for brain cancer, just add water. Story

Medical Device News

> Kinetic Concepts to be bought for $4.98B. News

> Medtronic asks for $2.5M to expand Jacksonville ops. Article

> Shuren talks CDRH performance, staffing in Boston. News

> Representatives discuss Scottish device, diagnostic biz. Story

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.